Latest Amides Stories
redOrbit Staff & Wire Reports - Your Universe Online Damage to the heart and lungs caused by treating tumors in a person’s chest area can be limited through the use of drug typically used to treat cardiovascular disease, a team of Dutch researchers claim in a new study. Dr. Sonja Van der Veen of the University Medical Centre, Groningen (UMCG), and colleagues intended to find out whether or not angiotensin-converting enzyme (ACE) inhibitors could help prevent a condition known as...
According to the Institute for Safe Medication Practices’ most recent QuarterWatch report, incretin mimetic drugs such as Byetta, Januvia and Victoza may be 25 times more likely to be linked to pancreatic cancer. This class of medications is currently under investigation by the U.S. Food and Drug Administration (FDA) after researchers found evidence of precancerous cell changes in pancreatic tissue samples from patients who took the Type 2 diabetes drugs. New York, New York (PRWEB) April...
DrugRisk is the Web’s largest source for information on prescription drug warnings, side effects and legal news. Visit http://www.DrugRisk.com New York, NY (PRWEB) April 18, 2013 The prescription drug safety advocates at DrugRisk.com are announcing the launch of a new resource center for patients who have taken the diabetes drug Januvia, amid warnings that the drug may be related to pancreatic cancer and thyroid cancer. The goal of DrugRisk is to improve patient safety by providing...
TORONTO, April 10, 2013 /CNW/ - Toronto law firm McPhadden Samac Tuovi LLP has commenced a proposed national class action against Boehringer Ingelheim relating to the blood thinner Pradax. The lawsuit is on behalf of all persons throughout Canada who ingested Pradax. The claim is for damages in the amount of $150,000,000. Pradax is used to prevent clotting in patients who suffer from atrial fibrillation (a condition in which the heart beats irregularly, increasing the chance...
The Rottenstein Law Group, a Pradaxa law firm, acknowledges the study and publicizes its Pradaxa page, which illustrates in detail the options for those who believe their medication has harmed them. New York, NY (PRWEB) April 05, 2013 On its website, Boehringer Ingelheim markets* blood-thinner Pradaxa as 35 percent more effective at reducing stroke than warfarin. But a recent study** presented at a Joint Session of the Heart Rhythm Society and the American College of Cardiology in San...
BOULDER, Colo., April 4, 2013 /PRNewswire/ -- Array BioPharma Inc. (NASDAQ: ARRY) today announced that results from two ongoing ARRY-520 clinical trials in multiple myeloma (MM) were presented at the 2013 International Myeloma Workshop in Kyoto, Japan. ARRY-520 is a potent, selective KSP inhibitor with a mechanism of action distinct from other drugs used to treat MM that continues to advance in clinical trials. (Logo: http://photos.prnewswire.com/prnh/20121029/LA02195LOGO) Results...
Now Enrolling Patients into Third Dosing Cohort SAN MARINO, Calif., April 4, 2013 /PRNewswire/ -- VG Life Sciences, Inc. (OTC Pink: VGLS), a biotechnology company focused on leveraging its innovative platform technologies for the discovery and development of drug therapies for cancer, infectious disease, and inflammation, announced today positive results from stage two of its Pre-IND Phase I Study to test tolerability and toxicity in patients with advanced stage solid tumors. The...
The Firm is currently investigating Pradaxa lawsuits on behalf of individuals who suffered life-threatening internal bleeding, allegedly due to Pradaxa side effects. New York, New York (PRWEB) March 28, 2013 As Pradaxa lawsuits continue to mount, Bernstein Liebhard LLP notes that a new study presented last week at the American College of Cardiology has raised questions about the effectiveness of new-generation blood thinners, including Pradaxa. The study, which aggregated data from three...
NEW YORK, March 26, 2013 /PRNewswire/ -- Pharmaceutical Executive, the monthly magazine and daily online publication of record on analytics, trends and personalities in the biopharmaceutical industry worldwide, announced today the choice for its 2013's drug Brand of the Year: Merck's Januvia [sitagliptin], a first in class dipeptide peptidase-4 inhibitor treatment for adult onset [Type II] diabetes. Brand of the Year is an independent, non-promotional designation, selected...
The Firm is currently investigating Pradaxa lawsuits on behalf of individuals who suffered life-threatening internal bleeding, allegedly due to Pradaxa side effects. New York, New York (PRWEB) March 24, 2013 Bernstein Liebhard LLP notes that the federal judge overseeing Pradaxa lawsuits in a federal multidistrict litigation in U.S. District Court, Southern District of Illinois has scheduled the litigation’s next status conference for April 15th at 1:00 p.m., according to the calendar...
